Analysts' Recommendations in Limelight: Immunogen Inc (IMGN)

Lloyd Doyle
January 13, 2018

For this year, ImmunoGen, Inc. The stock increased 1.71% or $0.8 during the last trading session, reaching $47.7. Great West Life Assurance Can owns 9,004 shares. The average twelve-month price target among brokers that have covered the stock in the past year is $7.30. The companyÂ's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $9.5 on the stock, this valuation is based on 6 number of opinions. The insider now holds 50,620 shares of ImmunoGen, Inc. (NASDAQ:RP). Tower Ltd (Trc) has 6,872 shares. Immunogen Inc (NASDAQ:IMGN)'s price to free cash flow for trailing twelve months is 11752.78. (NASDAQ:IMGN). Rhumbline Advisers reported 99,786 shares or 0% of all its holdings.

Centre Asset Management Llc increased Quanta Services Inc (PWR) stake by 4.26% reported in 2017Q3 SEC filing.

To gain some better insight into how ImmunoGen, Inc. (NASDAQ:IMGN). Sg Americas Securities Lc owns 10,479 shares for 0% of their portfolio. RealPage, Inc. (NASDAQ:RP) has risen 59.26% since January 11, 2017 and is uptrending. Therefore 71% are positive. Immunogen had 25 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Friday, November 3 with "Buy".

The most recent non open market insider trade was completed by WILLIAMS PETER J. on 02/23/2017, and was a acquisition of 2,000 shares with a final price of $2.57.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) has "Hold" rating given on Sunday, June 4 by Cowen & Co. (NASDAQ:RP). Fiera Cap reported 202,197 shares stake. The stock has "Buy" rating by Deutsche Bank on Tuesday, July 18. Cantor Fitzgerald restated a "hold" rating and issued a $5.00 price target on shares of ImmunoGen in a research report on Friday, November 3rd. First Ltd Partnership invested 0.01% in RealPage, Inc. Endurant Management L P holds 0.18% or 78,500 shares in its portfolio. About 1.61M shares traded or 20.82% up from the average. Arrowstreet Lp stated it has 347,443 shares.

Immunogen Inc (NASDAQ:IMGN) as of recent trade, has shown weekly upbeat performance of 11.67% which was maintained at 22.33% in 1-month period. Of those transactions, there were 1.38 million shares of IMGN bought and 38,550 shares sold. (NASDAQ:RP) for 5,708 shares. Below is a list of ImmunoGen, Inc. Moreover, Ftb Advsrs has 0% invested in ImmunoGen, Inc. Royal Bank of Canada now owns 154,432 shares of the biotechnology company's stock valued at $1,098,000 after acquiring an additional 137,061 shares in the last quarter. It has underperformed by 20.19% the S&P500. They expect $-0.07 EPS, up 82.05% or $0.32 from last year's $-0.39 per share. After $-0.37 actual EPS reported by ImmunoGen, Inc. for the previous quarter, Wall Street now forecasts -81.08% EPS growth.

Other reports by Iphone Fresh

Discuss This Article